[Intravenous immunoglobulins in autoimmune and inflammatory disorders: beyond a simple substitution].
Despite their widespread use since many years in autoimmune and inflammatory disorders, the mechanisms of action of IVIg have not been completely understood. These mechanisms depend on Fc and/or F(ab')2. IVIg interacts with the different components of the immune system: Fc receptors, complement, cytokines, T and B lymphocytes, dendritic cells, granulocytes and NK cells. Here, we discuss the recent advances in the understanding of the mechanisms of action of IVIg, in particular the importance of the sialylated Fc fragment. These advances maybe help us conceive better therapeutic strategies against autoimmune and inflammatory disorders.
Galeotti
C
C
Unité 872, Institut National de la Santé et de la Recherche Médicale, 75006 Paris, France.
Maddur
M S
MS
Kazatchkine
M-D
MD
Mouthon
L
L
Kaveri
S-V
SV
D001327:Autoimmune Diseases / Q000188:drug therapy*; D001402:B-Lymphocytes / Q000187:drug effects; D003713:Dendritic Cells / Q000187:drug effects; D006098:Granulocytes / Q000187:drug effects; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy*; D007694:Killer Cells, Natural / Q000187:drug effects; D011961:Receptors, Fc / Q000187:drug effects; D013601:T-Lymphocytes / Q000187:drug effects
D016756:Immunoglobulins, Intravenous; D011961:Receptors, Fc